Loading...
Loading...
Sucampo Pharmaceuticals, Inc. (“Sucampo”)
SCMP, a global
biopharmaceutical company, today announced that it has received orphan
drug designation in the European Union for unoprostone isopropyl for the
treatment of retinitis pigmentosa (RP). RP is a genetic disease
characterized by progressive, irreversible vision loss and decreasing
visual acuity, and there are no drugs or therapeutic procedures
currently approved for the treatment of RP today.
To qualify for orphan designation by the European Medicines Agency
(EMA), a medicine must be intended for the treatment, prevention or
diagnosis of a disease that is life-threatening or chronically
debilitating; the prevalence of the condition in the EU must not be more
than 5 in 10,000; and no satisfactory method
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in